Clinical Trial Update: PD-1 Antibody Plus Bevacizumab and CAPOX as First-line Treatment for RAS-mut MSS mCRC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating first-line therapy for RAS-mutant, microsatellite-stable metastatic colorectal cancer using a PD-1 antibody plus bevacizumab a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Capecitabine (capecitabine)
• OXALIPLATIN (Oxaliplatin)
• PD-1 antibody (PD-1 inhibitor)

Snippet

Sponsor: Chinese PLA General Hospital | Conditions: Colorectal Cancer, RAS Mutation | Phase 2 | Status: RECRUITING